Insider Sale: VP of $NTLA (NTLA) Sells 1,372 Shares

Quiver QuantitativeJan 7 17:33 ET

Beam Upgraded by Bernstein Ahead of AATD Data

Seeking AlphaJan 7 12:01 ET

RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $47

Moomoo NewsJan 7 09:35 ET · Ratings

RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk

MT NewswiresJan 7 07:39 ET · Ratings

BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $50

Moomoo NewsJan 7 07:31 ET · Ratings

Intellia Therapeutics Price Target Lowered to $50 From $58 at BofA

TipRanksJan 7 07:20 ET